| Bioactivity | OX2R-IN-1 (compound 15) is a low cytotoxicity profile OX2R-IN-1 antagonist (a potential OX2R binder) with an IC50 value of 484 μM. OX2R-IN-1 (compound 15) can cross the BBB into the brain with a short half-life[1]. |
| Target | IC50: 484 μM (OX2R) |
| Invitro | OX2R-IN-1 (compound 15) has low cytotoxic withIC50 values of 484 μM. OX2R-IN-1 (compound 15) is significant and dose-dependently reduce the signal of orexin A-evoked response (0.2 μM) in CHO-K1 cell line. OX2R-IN-1 (compound 15) has uncertain permeation through the BBB, since the PAMPA assay is limited by several drawbacks[1]. Cell Cytotoxicity Assay[1]. Cell Line: |
| In Vivo | OX2R-IN-1 (compound 15) has a short half-life and poor bioavailability. Animal Model: |
| Name | OX2R-IN-1 |
| CAS | 2639148-08-4 |
| Formula | C20H28ClN3O5S |
| Molar Mass | 457.97 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Eva Mezeiova, et al. From orexin receptor agonist YNT-185 to novel antagonists with drug-like properties for the treatment of insomnia, Bioorg Chem. 2020 Oct;103:104179. |
OX2R-IN-1
CAS: 2639148-08-4 F: C20H28ClN3O5S W: 457.97
OX2R-IN-1 (compound 15) is a low cytotoxicity profileOX2R-IN-1 antagonist (a potential OX2R binder) with an IC50 value o
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.